Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2013 by Gynecologic Oncology Group.
Recruitment status was:  Active, not recruiting
Sponsor:
Collaborators:
National Cancer Institute (NCI)
Genentech, Inc.
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Gynecologic Oncology Group
ClinicalTrials.gov Identifier:
NCT00886691
First received: April 22, 2009
Last updated: May 28, 2013
Last verified: May 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)